BioMedNewsBreaks

MondayJun 01, 2026 10:00 am

BioMedNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Shifts Focus to AI Energy Infrastructure, Adds Denham Capital Founder to Board

LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced a strategic transformation into an AI energy infrastructure equipment and services platform focused on supporting the growing power demands of artificial intelligence and hyperscale data centers. As part of the transition, Stuart D. Porter, founder, managing partner, CEO and chief investment officer of Denham Capital Management LP, has joined the company's board of directors. LIXTE said its strategy will target power equipment and service solutions for AI data-center campuses, distributed power systems and advanced generation technologies, while it seeks a strategic acquisition partner for its clinical-stage pharmaceutical and med-tech operations focused on cancer treatments.…

Continue Reading

FridayMay 29, 2026 12:27 pm

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances Simplified Cartilage Repair Platform Toward Key Commercial Milestones

Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing GelrinC®, a cell-free hydrogel implant designed to simplify knee cartilage repair through a single-step, approximately 10-minute procedure that may offer an alternative to traditional microfracture and complex cell-based therapies. The company is targeting an estimated $3 billion U.S. market encompassing roughly 470,000 annual knee cartilage repair cases, where no approved off-the-shelf regenerative solution currently exists. Clinical data have shown approximately 100% greater pain improvement versus microfracture, alongside MRI-confirmed regeneration of near-native cartilage and durable multi-year outcomes. GelrinC® has already secured CE Mark approval in Europe and is currently progressing through a pivotal…

Continue Reading

FridayMay 29, 2026 11:15 am

BioMedNewsBreaks — Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ) Signs LOI to Acquire Quantum Cybersecurity Company Quantum.IQ

This article has been disseminated on behalf of Redwood AI Corp. and may include paid advertising.  Redwood AI (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ)  announced it has entered into a non-binding letter of intent to explore the acquisition of Vancouver-based Quantum.IQ, an AI-driven quantum cybersecurity company focused on helping organizations prepare for emerging quantum-enabled cyber threats. Quantum.IQ's post-quantum cryptography platform is designed to assist government, defense, financial services and critical infrastructure organizations in assessing cryptographic vulnerabilities, planning migration to quantum-resistant security systems and monitoring ongoing cybersecurity readiness. Under the proposed transaction, Redwood would acquire all outstanding shares of Quantum.IQ in exchange for up to 14 million Redwood common shares, including milestone-based consideration, with all shares subject to a staged escrow release…

Continue Reading

ThursdayMay 28, 2026 12:43 pm

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Targets Major Gap in Knee Cartilage Repair Market with Off-the-Shelf Regenerative Implant

Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing GelrinC(R), a cell-free hydrogel implant designed to repair knee cartilage damage through a single approximately 10-minute procedure, positioning the company to address a major unmet need in orthopedic medicine. While roughly 472,500 arthroscopic knee procedures in the U.S. each year involve cartilage damage, no approved off-the-shelf regenerative solution capable of restoring hyaline-like cartilage currently exists in the U.S. market. Unlike traditional microfracture procedures or complex cell-based therapies that often require multiple surgeries and lengthy preparation, GelrinC(R) is designed as a ready-to-use implant that supports native cartilage regeneration over time. The product has…

Continue Reading

ThursdayMay 28, 2026 12:35 pm

BioMedNewsBreaks — Jupiter Neurosciences Inc. (NASDAQ: JUNS) Closes $2 Million Registered Direct Offering 

Jupiter Neurosciences (NASDAQ: JUNS), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, closed its securities purchase agreement for the sale of 7,142,858 shares of common stock in a registered direct offering with gross proceeds of approximately $2.0 million. D. Boral Capital LLC acted as the exclusive placement agent for the offering, which was conducted pursuant to the company’s effective shelf registration statement on Form S-3 declared effective by the U.S. Securities and Exchange Commission on April 24, 2026. To view the full press release, visit https://ibn.fm/uymqO About Jupiter Neurosciences, Inc. Jupiter Neurosciences, Inc. (NASDAQ: JUNS) is a clinical-stage biopharmaceutical company…

Continue Reading

ThursdayMay 28, 2026 10:35 am

BioMedNewsBreaks — VERAXA Biotech AG Secures $27.5 Million Senior Secured Financing and $50 Million Equity Line Ahead of Planned Nasdaq Listing 

VERAXA Biotech, a portfolio company of Xlife Sciences AG (SIX: XLS), secured $27.5 million in senior secured convertible note financing from High Trail Capital LP and entered into a share purchase agreement providing access to up to $50 million in equity financing with Lincoln Park Capital Fund LLC. The financing arrangements are intended to strengthen VERAXA’s financial position ahead of its planned business combination with Voyager Acquisition Corp. and anticipated listing on the Nasdaq Capital Market. The High Trail Capital financing includes a 15-month senior secured convertible note and warrants exercisable over four years at an initial exercise price of $11.50 per share, while the…

Continue Reading

ThursdayMay 28, 2026 10:11 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Nano to Present Deciparticle(TM) Nanomedicine Platform at BIO International Convention 2026 

Oncotelic Therapeutics (OTCQB: OTLC) and Sapu Nano announced that Chief Executive Officer Vuong Trieu will present the Deciparticle(TM) nanomedicine platform at the BIO International Convention 2026 in San Diego, highlighting the development of ultra-small nanomedicine formulations designed to enable intravenous administration of highly water-insoluble therapeutics. The Deciparticle(TM) platform utilizes proprietary amphiphilic polymer systems capable of forming sub-20 nanometer particles for oncology and other therapeutic applications. The companies plan to showcase development progress across multiple Deciparticle(TM) programs, including Sapu006, a polysorbate-free intravenous docetaxel formulation moving into Phase 1b clinical evaluation, and Sapu003, an intravenous everolimus nanomedicine program currently in a global Phase 1b clinical trial. The presentation will also highlight the integration…

Continue Reading

WednesdayMay 27, 2026 11:30 am

BioMedNewsBreaks — VolitionRx Ltd. (NYSE American: VNRX) Highlights Clinical and Commercial Progress Across Diagnostics Portfolio 

VolitionRx Limited (NYSE American: VNRX) provided a corporate update highlighting recent clinical and commercial progress, including submission of a feline lymphoma manuscript tied to a potential $5 million milestone payment, alongside continued momentum in licensing discussions with more than a dozen global diagnostic and liquid biopsy companies. The company also highlighted advancements across its diagnostic pipeline, including validation progress for its Capture-Seq cancer detection platform, expansion of its sepsis-focused Nu.Q NETs program and ongoing efforts to secure reimbursement in France for its lung cancer assay ahead of anticipated routine clinical use. To view the full press release, visit https://ibn.fm/nX9FK About Volition Volition is a multi-national company focused on…

Continue Reading

WednesdayMay 27, 2026 11:23 am

BioMedNewsBreaks — Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ) Gains DTC Eligibility, Engages IBN for Investor Awareness Campaign

This article has been disseminated on behalf of Redwood AI Corp. and may include paid advertising.  Redwood AI (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ) announced that its common shares have been approved for electronic clearing and settlement through the Depository Trust Company, a move expected to simplify trading for U.S. investors and enhance liquidity of the company’s shares. CEO Louis Dron said DTC eligibility improves access for U.S. investors and brokerage firms by enabling more efficient electronic clearing and settlement. The company also announced it has engaged InvestorBrandNetwork to provide market awareness, corporate communications and digital media services, including editorial coverage, newsletter distribution, social media support and podcast syndication through Sept. 30, 2026,…

Continue Reading

WednesdayMay 27, 2026 10:36 am

BioMedNewsBreaks — Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Featured in Diamond Equity Research Initiation Report Highlighting Commercial Psychedelics Opportunity

This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising.  Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) was featured in a newly published initiation report from Diamond Equity Research that highlights the company’s position as a commercial-stage psychedelic manufacturer with licensed GMP infrastructure, growing traction in Australia and potential operating leverage as prescription demand scales. The commissioned report cites Optimi’s regulatory licenses, existing MDMA and psilocybin manufacturing capacity, expanding commercial activity in Australia and longer-term U.S. optionality, while outlining an illustrative valuation based on discounted cash flow analysis. Diamond noted that Optimi’s asset-light strategy of supplying clinical trials rather than sponsoring them may reduce development…

Continue Reading